Technology | May 14, 2012

Biosense Webster Launches Thermocool SF Catheter With Curve Visualization


May 14, 2012 — Biosense Webster Inc. launched the new Thermocool SF (surround flow) Nav irrigated ablation catheter with Curve Visualization in the United States during the Heart Rhythm Society (HRS) scientific sessions last week in Boston.

The new irrigated ablation catheter combines Biosense Webster’s latest porous tip technology with the accurate visualization of the Carto3 3-D mapping and ablation system. This enhanced technology is designed to reduce fluoroscopy exposure to physicians, lab staff and patients alike, enhance visualization of the ablation catheters orientation and improve procedural efficiency.
 
The Thermocool SF increased the number of irrigation holes in the tip from six to 56 offers more efficient, uniform cooling than previous catheters.
 
Curve Visualization allows better visualization of the catheter in the Carto3 system. Previously only the tip was shown during procedures. The new system shows 40-90 mm of catheter to better show the orientation of the catheter and how it is supported inside the heart.
 
“The Thermocool SF catheter with Curve Visualization provides substantial advantages over existing technologies,” said Daniel Melby, M.D., cardiac electrophysiologist from the Minneapolis Heart Institute in Minneapolis, Minn., was among the first to use the new technology in the United States.  While using the Curve Visualization feature, the catheter position is more completely represented on the Carto display, thereby allowing less fluoroscopy use and easier catheter positioning on difficult atrial locations. In addition, the Thermocool SF platform provides the ability to consistently ablate at all atrial locations without the limitation of overheating and with 50 less volume delivery to the patient."
 
The catheter is approved in the United States for treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with Carto systems and Type 1 atrial flutter for patients 18 years and older.
 
For more information: www.biosensewebster.com
 

Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now